Viewing nowCombinationSitagliptin Metformin Extended Release Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
TDS Pharm Co., Ltd.

MFDS item code 202300612 · Approved 2023.02.17 · Insurance code 679802170
Improvement of glycemic control in patients with type 2 diabetes
This medication helps patients with type 2 diabetes control their blood sugar when taken along with dietary control and exercise. Sitagliptin and metformin work together to effectively lower blood sugar, playing an important role in diabetes management. Therefore, this medication is used to improve blood sugar control in patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. For this medicine 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and their current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at their current metformin dose of 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains both sitagliptin and metformin, primarily used for the treatment of type 2 diabetes. Serious allergic reactions may occur while taking this medication; therefore, if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, discontinue immediately and consult a doctor. Additionally, acute pancreatitis may occur, so if symptoms such as abdominal pain, vomiting, or nausea appear, seek medical attention promptly. The metformin component of this medication can, although rarely, cause a serious metabolic issue known as lactic acidosis. It should therefore not be administered to those with impaired kidney function, dehydration, severe infections, or heart disease. Patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, or those scheduled for examinations using radioiodine contrast should also avoid this medication. The safety of this medication has not been established for women who are pregnant or breastfeeding, and it should not be administered to children under 18. Regular monitoring of kidney function and blood tests should be conducted while taking this medication, and vitamin B12 levels may decrease, so supplementation may be necessary. Excessive alcohol consumption should be avoided while on this medication, and if eating patterns are irregular or strenuous exercise is undertaken, there is a risk of hypoglycemia, so caution is advised. If undergoing surgery, this medication should be discontinued 48 hours prior, and resumed only after stable conditions and normal kidney function have been confirmed post-surgery. The risk of hypoglycemia may increase when used with other hypoglycemic agents or certain medications, so all medications being taken must be disclosed to healthcare providers. During treatment, side effects such as diarrhea, nausea, headache, and upper respiratory infections may occur. If symptoms are severe or persistent, consult a doctor. Finally, when administering this medication to the elderly, dosage adjustments should be made considering reduced kidney function, and regular health evaluations are needed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is essential to maintain storage temperatures between 1 and 30 degrees Celsius to preserve the medication's efficacy.
Light blue, double convex, oval-shaped extended release film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
TDS Pharm Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.